NANT 2015-02: PHASE 1 STUDY OF LORLATINIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH ALK-DRIVEN RELAPSED OR REFRACTORY NEUROBLASTOMA

This Study is
No Longer Enrolling

Details
Age

Child

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 17-0511

More information available at ClinicalTrials.gov: NCT03107988

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers